Rathbones Group PLC Has $77.85 Million Holdings in Zoetis Inc. $ZTS

Rathbones Group PLC boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 532,064 shares of the company’s stock after acquiring an additional 27,590 shares during the quarter. Rathbones Group PLC’s holdings in Zoetis were worth $77,852,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC raised its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after buying an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its stake in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after acquiring an additional 1,422 shares in the last quarter. Finally, Sigma Planning Corp boosted its holdings in Zoetis by 3.1% during the 2nd quarter. Sigma Planning Corp now owns 3,325 shares of the company’s stock worth $518,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $121.54 on Friday. The company has a market capitalization of $51.31 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95. The business has a fifty day simple moving average of $126.06 and a two-hundred day simple moving average of $133.05. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the prior year, the firm earned $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several analyst reports. Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating for the company. Stifel Nicolaus decreased their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, Bank of America boosted their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.